List of Excipients in Branded Drug AMPHETAMINE EXTENDED-RELEASE ORAL SUSPENSION

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	AMPHETAMINE EXTENDED-RELEASE ORAL SUSPENSION	amphetamine	66993-360	CITRIC ACID MONOHYDRATE
Prasco Laboratories	AMPHETAMINE EXTENDED-RELEASE ORAL SUSPENSION	amphetamine	66993-360	CORN OIL
Prasco Laboratories	AMPHETAMINE EXTENDED-RELEASE ORAL SUSPENSION	amphetamine	66993-360	METHACRYLIC ACID
Prasco Laboratories	AMPHETAMINE EXTENDED-RELEASE ORAL SUSPENSION	amphetamine	66993-360	METHYLPARABEN

Amphetamine Extended-Release Oral Suspension: Excipient Strategy, Patent Risk, and Commercial Opportunities

Last updated: September 5, 2026

Amphetamine extended-release oral suspension is a differentiated pediatric ADHD dosage form built around dose flexibility, oral administration, and extended drug release. The leading U.S. reference product is Dyanavel XR, marketed by Tris Pharma under FDA NDA 208147. Its commercial position depends on the interaction between the amphetamine release matrix, taste and mouthfeel, suspension stability, dosing-device accuracy, controlled-substance controls, and formulation patent protection.

The strongest commercial opportunities are pediatric adherence, flexible titration, alternative dosage forms, preservative optimization, taste masking, and differentiated delivery devices. The principal competitive risk is a 505(b)(2) or generic entrant that reproduces the clinical profile with a simpler or lower-cost suspension system.

What drug is amphetamine extended-release oral suspension?

Amphetamine extended-release oral suspension is a liquid central nervous system stimulant indicated for attention deficit hyperactivity disorder. Dyanavel XR contains amphetamine hydrochloride at a labeled concentration of 2.5 mg/mL and is administered once daily. The product is intended for oral use and requires shaking before dosing to redisperse suspended drug particles.[1]

Attribute	Dyanavel XR
Active ingredient	Amphetamine hydrochloride
Dosage form	Extended-release oral suspension
Strength	2.5 mg/mL
FDA application	NDA 208147
Initial U.S. approval	2015
Therapeutic class	CNS stimulant
Primary population	Pediatric and adult ADHD patients
Regulatory status	FDA-approved prescription drug
Controlled-substance category	Schedule II
Administration	Once daily, with calibrated oral dosing device

The product competes with extended-release capsules, tablets, orally disintegrating tablets, chewable tablets, and immediate-release amphetamine formulations. The suspension format is most relevant for patients who cannot swallow solid dosage forms or require fine dose adjustments.

What excipients are used in amphetamine extended-release oral suspension?

The formulation uses excipients that support suspension stability, palatability, preservation, pH control, viscosity, and dose uniformity. The FDA label identifies inactive ingredients including citric acid, disodium edetate, glycerin, methylparaben, potassium sorbate, propylene glycol, sodium citrate, sodium saccharin, sucralose, xanthan gum, and flavoring components.[1]

Excipient function	Typical formulation role
Xanthan gum	Suspending agent and viscosity modifier
Glycerin	Humectant, solvent, and mouthfeel modifier
Propylene glycol	Co-solvent and flavor carrier
Citric acid and sodium citrate	Buffer system and pH adjustment
Methylparaben and potassium sorbate	Antimicrobial preservation
Disodium edetate	Chelating agent that can improve preservative performance
Sodium saccharin and sucralose	Sweetening and taste correction
Flavor system	Reduction of amphetamine bitterness and chemical aftertaste

The excipient system has to balance several competing requirements. Higher viscosity can improve suspendability but can make the product difficult to pour or draw into a syringe. Stronger sweetening can reduce bitterness but may leave an aftertaste or increase formulation complexity. Preservatives may improve multidose shelf life but can create pediatric tolerability, labeling, or regulatory concerns.

What excipient strategy is strongest for a new amphetamine suspension?

The most defensible strategy is a platform formulation that separates the active-release mechanism from the palatability and dosing systems. A competitor should avoid relying on a single excipient as the core differentiator.

Release-control strategy

Amphetamine can be incorporated into an ion-exchange resin, coated microparticle, polymeric matrix, lipid-based carrier, or other multiparticulate system. The commercial objective is a reproducible pharmacokinetic profile with reduced early peak exposure and once-daily duration.

The critical development variables include:

• Particle-size distribution
• Drug loading
• Polymer or coating permeability
• Ionic strength of the vehicle
• pH stability
• Agitation and settling behavior
• Food-effect sensitivity
• Release performance after dilution
• Dose uniformity at the beginning, middle, and end of the bottle

An ion-exchange resin system may provide strong control over release and taste, but resin selection, coating composition, and manufacturing conditions can create patent exposure. A polymer-coated multiparticulate system may provide better engineering flexibility but can increase process cost.

Suspending-agent strategy

Xanthan gum is commercially practical because it provides shear-thinning behavior, which helps the suspension remain stable at rest while allowing easier withdrawal through an oral syringe. Alternatives include hydroxyethyl cellulose, hydroxypropyl cellulose, sodium carboxymethylcellulose, microcrystalline cellulose blends, and structured suspending systems.

A differentiated product could target:

• Lower viscosity at the point of dosing
• Reduced sedimentation
• Faster redispersion after shaking
• Lower residual volume in the bottle
• Better compatibility with oral syringes
• Reduced foaming during shaking

The formulation must pass dose-uniformity testing throughout the in-use period. A suspension that is physically stable but difficult for caregivers to redisperse creates a direct adherence and liability risk.

Taste-masking strategy

Amphetamine has a strong bitter and medicinal taste. Sweeteners alone are unlikely to provide adequate masking. Commercially relevant approaches include polymer coating, ion pairing, resin complexation, lipid barriers, flavor layering, and pH optimization.

Taste masking must be tested after:

• Short residence in the mouth
• Dilution with water or juice, if permitted
• Repeated daily use
• Exposure to saliva conditions
• Storage and temperature cycling
• Administration through an oral syringe

Taste masking is a significant opportunity because pediatric refusal can eliminate the practical value of an otherwise effective formulation.

Preservative strategy

Dyanavel XR uses a multidose preserved liquid system. A next-generation product could pursue a lower-preservative or preservative-free presentation through a unit-dose sachet, prefilled oral syringe, single-use cup, or smaller bottle.

The trade-off is commercial. Multidose packaging reduces manufacturing and distribution cost, while unit-dose packaging can improve microbiological control and caregiver convenience. A preservative-free product may command a premium in selected pediatric or institutional settings, but packaging and fill-finish costs will increase.

What formulations are protected by patents?

Patent protection for amphetamine extended-release oral suspension can cover more than the active ingredient. Relevant claim categories include:

1. Extended-release amphetamine compositions.
2. Drug-resin complexes and coated particles.
3. Polymer matrices and multiparticulate systems.
4. Specific excipient ratios.
5. pH and viscosity ranges.
6. Taste-masked amphetamine particles.
7. Methods for treating ADHD with a liquid extended-release product.
8. Dosing regimens and pharmacokinetic profiles.
9. Bottles, oral syringes, and suspension-redispersion systems.
10. Manufacturing processes for drug loading, coating, drying, and blending.

The amphetamine molecule itself is old and cannot support meaningful composition-of-matter exclusivity. Commercial protection therefore depends on formulation, manufacturing, method-of-use, and device claims.

A freedom-to-operate review should distinguish between:

• Claims that require the same release technology.
• Claims that cover only specific excipient concentrations.
• Claims limited to a particular pharmacokinetic profile.
• Claims that cover the marketed product but not a materially different suspension.
• Orange Book-listed patents versus non-listed manufacturing or platform patents.

Patent strength is highest when formulation claims are tied to measurable product attributes, such as a defined release profile, particle architecture, or dose-uniformity result. Broad claims directed only to “an extended-release liquid amphetamine composition” are more vulnerable to written-description, enablement, obviousness, and claim-construction challenges.

When does amphetamine extended-release suspension lose exclusivity?

Dyanavel XR does not have biologic exclusivity because it is a small-molecule drug. The relevant exclusivity mechanisms are New Chemical Entity exclusivity, pediatric exclusivity, formulation patents, method-of-use patents, and regulatory exclusivity associated with the approved NDA.

The five-year NCE period generally applies only when the active moiety qualifies as a new chemical entity. Amphetamine does not qualify as a newly discovered active moiety for a later liquid formulation. A later dosage form may receive three-year exclusivity for a new clinical investigation essential to approval, but that protection is narrower and does not block all ANDA activity.

Pediatric exclusivity can add six months to qualifying FDA exclusivity and patent terms. The exact commercial loss-of-exclusivity date depends on the Orange Book patent list, patent-term adjustments, pediatric extension, litigation outcomes, and any settlement agreement.

What is the Orange Book status of Dyanavel XR?

Dyanavel XR is listed in the FDA Orange Book as an approved prescription product associated with NDA 208147.[2] The relevant Orange Book analysis should focus on whether listed patents cover the drug substance, drug product, or method of use and whether any listed patent has expired, been delisted, or been subject to a Paragraph IV notice.

For a generic or follow-on sponsor, the key regulatory options are:

Pathway	Commercial relevance
ANDA	Possible if the product can demonstrate pharmaceutical equivalence and bioequivalence
505(b)(2) NDA	Relevant if the product uses a different formulation, release system, strength, device, or clinical bridge
Full NDA	Unlikely unless the sponsor cannot rely sufficiently on the reference product
Authorized generic	Could enter through a license or commercial arrangement with the NDA holder

A liquid extended-release stimulant may create more complex bioequivalence questions than an immediate-release tablet. The sponsor may need comparative pharmacokinetic studies, in vitro release work, food-effect analysis, and evidence that the suspension delivers consistent doses across the bottle.

Which companies are challenging amphetamine extended-release oral suspension?

The competitive field includes branded stimulant manufacturers, generic amphetamine manufacturers, and specialty formulation companies. Direct public evidence of a settled Paragraph IV challenge should be confirmed from FDA litigation records, district court dockets, and the Orange Book before relying on a specific entrant or launch date.

The main potential challengers are:

• Generic manufacturers with experience in controlled-release stimulants.
• Companies with liquid multiparticulate technology.
• Pediatric specialty pharmaceutical companies.
• Firms developing 505(b)(2) products with alternative taste-masking systems.
• Manufacturers using orally disintegrating or chewable amphetamine formats as substitutes.

The absence of a simple tablet-to-liquid conversion is commercially important. A generic sponsor must replicate the reference product’s release and dose performance without necessarily using the same excipient architecture.

What generic entry risks exist?

The highest-risk scenario is a successful Paragraph IV challenge against the primary formulation patents followed by a technically credible ANDA product. A second scenario is a 505(b)(2) product that avoids key formulation claims while offering a similar duration of action.

Generic entry could take three forms:

Direct liquid generic

This product would target the same active ingredient, concentration, dosage form, route, and extended-release profile. It would compete most directly on price and payer substitution.

Alternative liquid formulation

A 505(b)(2) product could use a different suspension system, taste-masking technology, preservative profile, or delivery device. This product may avoid some patent claims but could require additional clinical or bridging data.

Solid-dose substitute

Extended-release capsules, chewables, and orally disintegrating tablets can capture patients who do not require a liquid. These products reduce the value of suspension-specific differentiation.

The economic impact depends on payer substitution, pharmacy stocking, Medicaid reimbursement, and whether physicians consider the products clinically interchangeable.

How does amphetamine suspension compare with competing ADHD products?

Product format	Main advantage	Main limitation
Extended-release oral suspension	Flexible dosing and no swallowing requirement	Bottle handling, settling, preservative and taste challenges
Extended-release capsule	Convenient once-daily use	Swallowing barrier; limited dose increments
Chewable tablet	Easier administration than a capsule	Taste, chewing ability, solid-dose limitations
Orally disintegrating tablet	Rapid administration without water	Dose flexibility may be narrower
Immediate-release liquid	Fine titration and established use	Multiple daily dosing and shorter duration
Transdermal system	Avoids oral administration	Skin reactions, wear-time and controlled-substance concerns

The suspension has the strongest fit in children who need small dose adjustments, cannot swallow pills, or respond poorly to the exposure profile of other stimulants. It has less differentiation in older adolescents and adults who can use capsules or tablets.

What licensing deals and commercial partnerships are relevant?

Tris Pharma is the principal commercial entity associated with Dyanavel XR. The product is part of Tris’s broader portfolio of liquid and specialty dosage forms. Publicly reported licensing arrangements specific to Dyanavel XR should be separated from broader corporate licensing, distribution, or co-promotion agreements.

Potential licensing assets include:

• Ion-exchange resin technology
• Taste-masking platforms
• Pediatric liquid suspension systems
• Controlled-release microparticle manufacturing
• Preservative-free multidose packaging
• Dose-tracking or oral-syringe technologies
• Regional rights outside the United States

A transaction would be more attractive if it includes manufacturing know-how, validated release methods, patent families, regulatory data, and freedom to operate. A license limited to a formulation patent without scalable manufacturing support would have lower strategic value.

What manufacturing and IP barriers limit entry?

Manufacturing is a meaningful barrier because the product must combine controlled release with a stable, palatable suspension. Key process steps may include drug loading, particle coating, drying, milling, size classification, blending, and final suspension manufacture.

Important barriers include:

• Reproducible coating thickness
• Low batch-to-batch variability
• Prevention of particle aggregation
• Uniform drug concentration during filling
• Stability under temperature excursions
• Compatibility with preservative systems
• Cleaning validation for a Schedule II stimulant
• Controlled-substance inventory reconciliation
• Child-resistant packaging and calibrated dosing devices

The strongest manufacturing moat is usually process knowledge rather than a single excipient. Scale-up can change particle morphology, viscosity, sedimentation, and release behavior even when the formulation composition remains unchanged.

What commercial opportunities exist for new excipient systems?

The most attractive opportunities are:

1. Preservative-free unit-dose or prefilled-syringe presentations.
2. Lower-viscosity suspensions with rapid redispersion.
3. Improved bitterness suppression without excessive sweetness.
4. Longer in-use stability after opening.
5. Lower-residual-volume bottles and oral syringes.
6. Formulations compatible with food or beverage administration.
7. Smaller pediatric dose increments.
8. Reduced food-effect variability.
9. Packaging designed for school and caregiver use.
10. Global formulations using excipients accepted in multiple jurisdictions.

An excipient supplier can create value by delivering a complete platform rather than a single ingredient. The platform should include composition, process parameters, analytical methods, stability data, and regulatory support.

What FDA regulatory issues affect development?

FDA review will focus on product quality, pharmacokinetics, dose uniformity, microbial quality, stability, labeling, and controlled-substance requirements. Excipients already used in oral products have a regulatory advantage, but pediatric exposure, daily dose, route, and concentration remain relevant.

A new product should anticipate scrutiny of:

• Excipient safety at the maximum daily dose
• Preservative exposure
• Alcohol or propylene glycol content
• Mutagenic impurities
• Extractables and leachables
• Microbial limits
• Dose delivery after shaking
• In-use stability
• Container closure integrity
• Abuse-related product characteristics

Biosimilar risk is not applicable because amphetamine is a synthetic small-molecule drug. The relevant follow-on risks are ANDA substitution and 505(b)(2) competition.

Key Takeaways

• Dyanavel XR is the leading U.S. reference product for amphetamine extended-release oral suspension.
• The formulation opportunity is concentrated in release control, taste masking, suspension stability, preservation, and dosing-device performance.
• Amphetamine has no meaningful new-molecule exclusivity for a later liquid formulation; protection depends on formulation, method-of-use, process, and device patents.
• A direct generic may face complex bioequivalence and manufacturing requirements, but a successful Paragraph IV challenge could materially reduce pricing power.
• A 505(b)(2) product with a different release or excipient system is a credible competitive pathway.
• Preservative-free packaging, improved redispersion, better taste masking, and prefilled dosing devices offer the clearest commercial differentiation.
• Manufacturing know-how and controlled-substance controls can be as important as patent protection.
• Licensing value is highest when formulation rights are bundled with scalable manufacturing, analytical methods, and regulatory data.

FAQs About Amphetamine Extended-Release Oral Suspension

Can amphetamine extended-release oral suspension be administered with food?

Food administration depends on the approved product label and formulation-specific pharmacokinetic data. A new formulation should generate food-effect data because changes in gastric conditions can alter release and absorption.

Is amphetamine extended-release oral suspension eligible for an ANDA?

Potentially. The sponsor must establish pharmaceutical equivalence and demonstrate bioequivalence to the reference product. Differences in release technology, excipients, device, or labeling may make a 505(b)(2) NDA more appropriate.

What is the main excipient risk in pediatric amphetamine suspension?

The main risks are bitterness, preservative exposure, viscosity-related dosing error, sedimentation, and inadequate redispersion. These risks affect both regulatory review and real-world adherence.

Can a preservative-free amphetamine suspension be commercialized?

Yes, but the product would require packaging and microbiological controls appropriate for a multidose or unit-dose liquid. Prefilled oral syringes and single-use containers are potential approaches.

Does amphetamine extended-release suspension have biosimilar competition?

No. Biosimilar regulation applies to biological products. Amphetamine follow-on competition would arise through generic, 505(b)(2), authorized-generic, or other small-molecule pathways.

References

1. U.S. Food and Drug Administration. (2023). Dyanavel XR prescribing information. Tris Pharma, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2019). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant or natural origin. FDA.

4. U.S. Food and Drug Administration. (2020). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA.

5. U.S. Food and Drug Administration. (2016). Safety and effectiveness of excipients in pediatric drug products. FDA.